B Medical Systems is teaming up with the US-based technology company SEEDR
The Luxembourg and US-based companies are taking on the challenge of developing a new range of intelligent Grade-A passive freeze-free technology. The new devices, under review by the World Health Organization’s (WHO) standards and safety division, promise to help protect millions of children from infectious diseases by ensuring potent vaccines in the remotest locations of the world.
According to UNICEF, an estimated 19.9 million infants worldwide were not reached with routine immunization services in 2017.i As vaccines are temperature-sensitive, their transport requires a constant temperature between 2-8°C all the way from the manufacturer to the end-users, even when it comes to populations living in the remotest rural areas of the world. Insulated transport technologies help shield vaccines from damage caused by heat. Yet too much ice can cause them to freeze. Once exposed to sub-zero temperatures, approximately 85% of routine vaccines lose their potency and must be immediately discarded or risk vaccinating children with an ineffective, or worse, harmful antigen. Studies of cold chain performance show that between 75 and 100% of vaccine shipments are exposed to freezing temperatures.
The partnership between B Medical Systems and SEEDR will launch the next generation of intelligent vaccine carriers and transport boxes using new production technologies and materials. The new devices will prevent inadvertent vaccine freezing and help ensure every child is protected against vaccine-preventable diseases, answering the call to industry put out from Gavi, the Vaccine Alliance. Gavi spends over $1 billion a year to help countries vaccinate over 60 million children annually and has called for new cold chain technology to help countries keep pace with the massive increase in the value and quantity of vaccines.
SEEDR and B Medical Systems have already commenced work focused on the optimization, manufacturing, and commercialization of the new devices. Expected to be launched in early 2019, the new product family will not only provide Grade-A freeze protection, but also several other powerful new features to revolutionize the broader passive transport industry for a range of temperature-sensitive biologics, including blood and plasma, biological samples for diagnostics and surveillance, vaccines and other pharmaceuticals.